A plea for open source pharmaceutical development

Stiglitz argues that the human cost of pharmaceutical intellectual property is exacted primarily from the developing world, which cannot afford current drugs and is blocked from developing or using generic alternatives. Meanwhile, new drug development targets very few developing world diseases, primarily because their victims are poor and cannot support the cost of the research involved. It’s at this point that the editorial gets somewhat confused; it’s not clear whether Stiglitz views the pharmaceutical companies as embodiments of the problem, or passive victims of economic reality. He slams the companies for spending more on advertising than research, and more on lifestyle drugs than those that target diseases. In the same paragraph, however, Stiglitz notes that “poor people cannot afford drugs, and drug companies make investments that yield the highest returns,” and suggests that even a company he praises as socially responsible is helpless in the face of that economic reality.

Read this article from Ars Technica. Original Editorial from bmj.com.


Leave a comment

Filed under Open Source

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s